5α-Reductase Inhibitors (5ARIs) and Male Reproduction
- PMID: 29256127
- DOI: 10.1007/978-3-319-69535-8_7
5α-Reductase Inhibitors (5ARIs) and Male Reproduction
Abstract
The 5ARIs, finasteride and dutasteride, are used to treat benign prostate hyperplasia and lower urinary tract symptoms. At much lower doses, 5ARI treatment reduces male hair loss. These drugs inhibit the conversion of testosterone to the more active dihydrotestosterone (DHT). In men taking these medications, DHT levels are reduced by some 90% while testosterone levels remain relatively stable. Well known for their negative effects on libido and erectile function, 5ARIs also cause ejaculatory dysfunction in some men, having the potential to decrease semen quality. In fact, some studies of men treated with these drugs have reported lower total sperm count, along with lower sperm motility, although the changes are probably insufficient to reduce fertility in men with normal semen before treatment. There is a population of men with more severely decreased sperm numbers; as low as 10% of pretreatment values. Fewer studies have looked at the lower doses used for male alopecia, indicating little affect in men with normal semen quality, but a negative effect on sperm numbers in men with oligozoospermia. There have been no studies looking at fertility endpoints for these medications.
Similar articles
-
Sexual dysfunction in subjects treated with inhibitors of 5α-reductase for benign prostatic hyperplasia: a comprehensive review and meta-analysis.Andrology. 2017 Jul;5(4):671-678. doi: 10.1111/andr.12353. Epub 2017 Apr 28. Andrology. 2017. PMID: 28453908 Review.
-
Dihydrotestosterone and the concept of 5alpha-reductase inhibition in human benign prostatic hyperplasia.Eur Urol. 2000 Apr;37(4):367-80. doi: 10.1159/000020181. Eur Urol. 2000. PMID: 10765065 Review.
-
Dihydrotestosterone and the concept of 5alpha-reductase inhibition in human benign prostatic hyperplasia.World J Urol. 2002 Apr;19(6):413-25. doi: 10.1007/s00345-002-0248-5. World J Urol. 2002. PMID: 12022710 Review.
-
Effect of 5α-Reductase Inhibitors on Sexual Function: A Meta-Analysis and Systematic Review of Randomized Controlled Trials.J Sex Med. 2016 Sep;13(9):1297-1310. doi: 10.1016/j.jsxm.2016.07.006. Epub 2016 Jul 27. J Sex Med. 2016. PMID: 27475241 Review.
-
5-alpha reductase inhibitors and erectile dysfunction: the connection.J Sex Med. 2008 Dec;5(12):2917-24. doi: 10.1111/j.1743-6109.2008.01001.x. J Sex Med. 2008. PMID: 19090946 Review.
Cited by
-
Exploring the Enigma of 5-ARIs Resistance in Benign Prostatic Hyperplasia: Paving the Path for Personalized Medicine.Curr Urol Rep. 2023 Dec;24(12):579-589. doi: 10.1007/s11934-023-01188-z. Epub 2023 Nov 21. Curr Urol Rep. 2023. PMID: 37987980 Review.
-
Inverse androgenic alopecia.BMJ Case Rep. 2023 Oct 31;16(10):e254361. doi: 10.1136/bcr-2022-254361. BMJ Case Rep. 2023. PMID: 37907317
-
Efficacy of a combination of dutasteride, tadalafil, and solifenacin in the treatment of previously unsuccessful patients.Asian J Urol. 2022 Jan;9(1):42-50. doi: 10.1016/j.ajur.2021.04.002. Epub 2021 Apr 20. Asian J Urol. 2022. PMID: 35198395 Free PMC article.
-
Serum concentrations of dihydrotestosterone are associated with symptoms of hypogonadism in biochemically eugonadal men.J Endocrinol Invest. 2021 Nov;44(11):2465-2474. doi: 10.1007/s40618-021-01561-0. Epub 2021 Apr 3. J Endocrinol Invest. 2021. PMID: 33811609 Free PMC article.
-
Improvement of the symptoms of lower urinary tract and sexual dysfunction with tadalafil and solifenacin after the treatment of benign prostatic hyperplasia with dutasteride.Prostate Int. 2020 Jun;8(2):78-84. doi: 10.1016/j.prnil.2019.11.005. Epub 2020 Feb 25. Prostate Int. 2020. PMID: 32647644 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
